Delving into the Latest Updates on Indomethacin with Synapse

Overview

Basic Info

SummaryIndomethacin, a diminutive molecule that belongs to the illustrious class of nonsteroidal anti-inflammatory drugs (NSAIDs), works by inhibiting the COX enzyme, thereby impeding inflammation and pain. This drug, can be used for a vast spectrum of maladies including ductus arteriosus, periarthritis, tennis elbow, acute brachial neuritis, gouty arthritis, ankylosing spondylitis, bursitis, tendinopathy, osteoarthritis, rheumatoid arthritis, tumescence, pain, elbow tendinopathy, inflammation, and musculoskeletal pain, is celebrated for its versatility. The roots of this pioneering drug, originally cultivated by the esteemed iROKO Partners Ltd., can be traced back to June 1965, when it first received its approval. With its COX inhibiting properties, indomethacin engenders a plethora of benefits by effectively mitigating inflammation and providing pain relief in a wide range of conditions.

Drug Type

Small molecule drug

Synonyms

IM-P, Indaflex, Indometacin

+ [32]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [5]

Active Indication

Ductus Arteriosus, PatentInflammationMyalgia+ [13]

Inactive Indication

Acute migraineAcute PainLow Back Pain+ [5]

Originator Organization

IROKO Ltd.

Active Organization

Hisamitsu Pharmaceutical Co., Inc.

Kowa Co., Ltd.

Teika Pharmaceutical Co., Ltd.

+ [8]

Inactive Organization

Rising Pharmaceuticals, Inc.

Novartis AGMerck Frosst Canada Ltd.

+ [5]

License Organization

Zyla Life Sciences LLC

Iroko Pharmaceuticals LLC

Drug Highest PhaseApproved

First Approval Date

United States (10 Jun 1965),

Ankylosing SpondylitisBursitisOsteoarthritis+ [4]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H16ClNO4

InChIKeyCGIGDMFJXJATDK-UHFFFAOYSA-N

CAS Registry53-86-1

主要目的：以吲哚美辛的主要药代动力学参数（AUC和Cmax）为生物等效性的评价指标，在中国健康受试者外用条件下评估受试制剂【海南回元堂药业有限公司申报的吲哚美辛凝胶贴膏，规格：每贴（14cm×10cm）含膏体14g，含吲哚美辛70mg】和参比制剂【帝國製薬株式会社持证的吲哚美辛凝胶贴膏剂，规格：每贴（14cm×10cm）含膏体14g，含吲哚美辛70mg；商品名：Catlep®】的生物等效性。次要目的：观察外用条件下受试制剂和参比制剂的黏附性、皮肤刺激性和安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test formulation [Indomethacin Gel Patch (application submitted by Hainan Huiyuantang Pharmaceutical Co., Ltd., specification: 14g of ointment per patch (14cm×10cm), containing 70mg of indomethacin)] and the reference formulation [Indomethacin Gel Patch (licensed by Teikoku Pharmaceutical Co., Ltd., specification: 14g of ointment per patch (14cm×10cm), containing 70mg of indomethacin; trade name: Catlep®)] under topical application conditions in healthy Chinese subjects, using the main pharmacokinetic parameters (AUC and Cmax) of indomethacin as bioequivalence indicators. Secondary objective: To observe the adhesion, skin irritation, and safety of the test and reference formulations under topical application conditions.

Start Date29 Dec 2025

Sponsor / Collaborator

Hainan Huiyuantang Pharmaceutical Co Ltd

NCT07247682

/ Not yet recruitingPhase 4IIT

Dose-escalation of Rectal Indomethacin for Post-ERCP Pancreatitis Prevention in High-risk Patients: Protocol of a Multicentre Randomised Clinical Trial

Our aim is to compare the efficacy of 100 mg versus 200 mg rectal indometacin in preventing post-ERCP pancreatitis (PEP) among high-risk patients without no pancreatic stenting. The 100 mg versus 200 mg indometacin trial is a multicentre, single-blind, randomized controlled study. High-risk patients for PEP without pancreatic stent insertion will be informed about the opportunity to participate. A total of 1,036 eligible patients will be randomly assigned in a 1:1 ratio to one of two groups: (1) administration of 100 mg rectal indometacin immediately after ERCP (standard-dose group), or (2) administration of 200 mg rectal indometacin immediately after ERCP (high-dose group). The primary outcome is the incidence and severity of PEP. Secondary outcomes include hyperamylasemia and other ERCP-related adverse events (AEs).

Start Date01 Dec 2025

Sponsor / Collaborator

Anhui Medical University No. 1 Affiliated Hospital

100 Clinical Results associated with Indomethacin

Login to view more data

100 Translational Medicine associated with Indomethacin

Login to view more data

100 Patents (Medical) associated with Indomethacin

Login to view more data

41,317

Literatures (Medical) associated with Indomethacin

01 May 2026·JSES reviews, reports, and techniques

Postoperative nonsteroidal anti-inflammatory drug prophylaxis for elbow heterotopic ossification: a systematic review and meta-analysis comparing COX-2 selective and nonselective inhibitors

Review

Author: Oh, Luke S ; Khorram, Roya ; Huffman, G Russell ; Ghayyad, Kassem ; Ahmad, Areeb ; Kachooei, Amir R ; Amin, Vraj ; Osbahr, Daryl C

Background:

Heterotopic ossification (HO) is a significant complication following elbow trauma and surgery, leading to pain, stiffness, and functional impairment. While nonsteroidal anti-inflammatory drugs (NSAIDs) have been extensively investigated for HO prophylaxis, their effectiveness in preventing postoperative HO in the elbow remains unclear. This study aims to compare the efficacy of selective vs. nonselective NSAIDs in reducing postoperative HO rates after traumatic elbow surgeries.

Methods:

This systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search was performed in PubMed, Embase, Cochrane Library, and Web of Science from January 2004 to January 10, 2025. Level I-III studies were included if they examined patients who underwent elbow surgery following trauma and compared selective COX-2 inhibitors or nonselective NSAIDs to no prophylaxis, with reported postoperative HO formation rates.

Results:

A total of 2,429 articles were identified across the four databases. Following full-text review, 1 randomized control trial and 5 retrospective studies were included in the quantitative synthesis, comprising patients who underwent either acute post-traumatic surgery or postexcision/open arthrolysis for established HO. Both selective (celecoxib) and nonselective (indomethacin) NSAIDs demonstrated no statistically significant difference in reducing postoperative HO compared with controls (celecoxib: risk ratio = 0.64, 95% confidence interval 0.32-1.31, P = .22; indomethacin: risk ratio = 0.87, 95% confidence interval 0.65-1.18, P = .38). Nonselective (indomethacin and ibuprofen) and selective (celecoxib) NSAID prophylaxis significantly reduced HO incidence compared to controls (P = .007), demonstrating a 27% relative risk reduction.

Conclusion:

This study demonstrates that both selective (celecoxib) and nonselective (indomethacin and ibuprofen) NSAIDs effectively reduce the risk of HO following elbow trauma surgery. When analyzed individually, neither the selective COX-2 inhibitor (celecoxib) nor the nonselective NSAIDs (indomethacin, ibuprofen) showed a statistically significant difference compared with controls, indicating no clear difference in efficacy between NSAID classes. However, given the limited number of studies and interstudy heterogeneity, the overall power of the current evidence is low, and further prospective research is needed to validate these findings.

01 Apr 2026·MICROBIAL PATHOGENESIS

Natural supplements effectively suppress Helicobacter pylori colonization and improve gastric antioxidant and antiinflammatory responses in an indomethacin-induced ulcer model

Article

Author: Kocak Sezgin, Ayse ; Açikgoz, Birkan ; Koldemir Gunduz, Meliha ; Aydin, Elif ; Simsek, Sercan ; Kaymak, Güllü

BACKGROUND:

The coexistence of Helicobacter pylori (H. pylori) infection and use of non-steroidal anti-inflammatory drugs (NSAIDs) is very common in clinics and they act together to worsen the gastric damage. The growing resistance to antibiotics and the side effects of the eradication regimens support the use of multi-target supportive strategies. The study aimed to determine the antibacterial, antibiofilm, antioxidant, and anti-inflammatory effects of three natural supplements as well as their effect on HIF-1α and TGF-β expression in a rat model of indomethacin-induced H. pylori gastric ulcer.

METHODS:

The in vitro anti-H. pylori activity of the two formulations (Nitro-plus and Sunset) was evaluated by determining the minimum inhibitory concentration (MIC) and using resazurin microdilution methods, along with antibiofilm assays conducted in 96-well plates. The experiment was carried out on female Wistar rats, which were allocated to six groups: healthy control, indomethacin-induced ulcer, H. pylori + gastritis ulcer, gastritis ulcer + natural supplements, H. pylori + gastritis ulcer + natural supplements, and H. pylori + gastritis ulcer + standard triple therapy. Indomethacin (5 mg/kg) was the agent used for inducing ulcers, and the presence of H. pylori was determined by testing for fecal antigen and urease. After a 30-day period of different treatments, the gastric tissues were assessed for the following parameters: urease activity, bacterial load (CFU/g), IL-1β and IL-10 levels (ELISA), HIF-1α and TGF-β expression (qPCR), as well as total antioxidant status (TAS) and total oxidant status (TOS) measurements, malondialdehyde (MDA), catalase (CAT), and glutathione (GSH) levels, and histopathology.

RESULTS:

Nitro-plus and Sunset presented notable anti-H. pylori activities (MIC 2.2 and 0.406 mg/mL without resazurin) and also antibiofilm activities, with the inhibition of biofilm biomass being ∼58 % and ∼47 %, respectively. In vivo, natural supplements, in decreasing the gastric burden of H. pylori, reducing the urease activity, lowering the levels of IL-1β and HIF-1α, and raising the level of IL-10 as compared to the untreated H. pylori + ulcer group, had effects comparable to triple therapy in several parameters. The TOS and MDA levels were lowered while the TAS, CAT and GSH levels were increased, thus the histological scores were also improved due to the attenuation of inflammation, neutrophil activation, and bacterial colonization.

CONCLUSION:

The use of multi-component natural supplements that addressed bacterial load, biofilm formation, oxidative stress, inflammatory cytokines and hypoxia-related pathways reduced the effects of indomethacin and H. pylori in causing gastric damage and made the supplements a good candidate for adjunctive support in standard eradication regimens. The clinical trials should be controlled and conducted to confirm the translational relevance.

01 Mar 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Rational design of an NLRP3 inhibitor with superior efficacy and safety for gout therapy

Article

Author: Jiang, Caihong ; Ren, Shuhua ; Guo, Yue ; Kong, Yichao ; Huang, Weiwei ; Hu, Yingjie ; Qiu, Ting ; Zhu, Fuli ; Mao, Zhenyu ; Yuan, Yaxia ; Feng, Haonan ; Li, Donglai ; Chi, Man ; Su, Mengjun ; Liu, Fengling ; Ma, Lei ; Chen, Xiabin

Gout, driven by urate crystal-induced inflammation, remains a therapeutic challenge due to the limited efficacy and toxicity of current treatments. Targeting the NLRP3 inflammasome, a central driver of gout pathogenesis, offers a promising strategy. While MCC950, a potent NLRP3 inhibitor, demonstrated clinical potential, its discontinuation due to hepatotoxicity underscores the urgent need for safer alternatives. Here, we address these challenges through a rational drug design approach to develop next-generation NLRP3 inhibitors. By leveraging cryo-EM structures and molecular dynamics (MD) simulations of the MCC950-NLRP3 complex, we identified a structurally dynamic region near the furan moiety and an adjacent unoccupied hydrophobic pocket. Systematic structural optimization targeting this pocket enabled the design of M48, a derivative that exhibited superior anti-inflammatory activity (IC₅₀ = 11.9 nM), favorable oral bioavailability (89.7 % in rats), and an improved safety profile compared to MCC950. In an MSU-induced mouse gout model, M48 demonstrates superior anti-inflammatory and analgesic effects compared to indomethacin, with efficacy comparable to colchicine. The design strategy, grounded in computational insights into ligand-protein interactions, demonstrates both scientific rigor and broad applicability for optimizing small-molecule inhibitors. Notably, M48's enhanced efficacy and reduced liver toxicity risk validate the approach's potential for addressing unmet clinical needs in gout and other NLRP3-associated diseases.

32

News (Medical) associated with Indomethacin

17 Dec 2025

·www.drugs.com

Expectant Management Matches Active Treatment in Preemies With Patent Ductus Arteriosus

WEDNESDAY, Dec. 17, 2025 -- For extremely preterm infants with protocol-defined patent ductus arteriosus (PDA), the incidence of death or bronchopulmonary dysplasia (BPD) does not differ with expectant management versus active treatment, according to a study published online Dec. 9 in the Journal of the American Medical Association . Matthew M. Laughon, M.D., M.P.H., from the University of North Carolina at Chapel Hill, and colleagues conducted a randomized clinical trial involving infants born at 22 to 28 weeks of gestation and diagnosed with a protocol-defined PDA between the ages of 48 hours and 21 days. Infants with PDA were randomly assigned to receive either expectant management or active treatment ( acetaminophen , ibuprofen, or indomethacin ) to close the PDA (242 and 240 infants, respectively). After the 50 percent interim analysis for the primary outcome of death at 36 weeks of postmenstrual age, the trial was stopped for futility and safety due to higher survival in the expectant management group. The researchers found that the incidence of death or BPD was 80.9 and 79.6 percent in the expectant management and active treatment groups, respectively (adjusted risk difference, 1.2 percent; 95 percent confidence interval, −5.7 to 8.1 percent; P = 0.73). The incidence of death before 36 weeks of postmenstrual age was 4.1 and 9.6 percent in the expectant management and active treatment groups, respectively (adjusted risk difference, −5.6 percent; 95 percent confidence interval, −10.1 to −1.2 percent; P = 0.01). Infections resulting in death occurred in 0.8 and 3.8 percent in the expectant management and active treatment groups, respectively. "This trial showed no benefit of active treatment of the PDA in extremely preterm infants," Laughon said in a statement. "In fact, it identified a higher chance of survival for expectant management, consistent with emerging data on the effects of early (i.e., prior to one or two weeks after birth) pharmacologic PDA treatment." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text

Clinical ResultClinical Study

15 Dec 2025

·www.drugs.com

Doing Nothing Appears Best Approach To Common Heart Defect Among Preemies

MONDAY, Dec. 15, 2025 — Doing nothing at all to manage a common fetal heart defect might improve the survival odds of babies born prematurely, compared to treatment with drugs, a new clinical trial suggests. A “wait and see” approach to patent ductus arteriosus (PDA) doubled a preemie’s chances of survival, compared with using drugs to treat the condition, researchers reported Dec. 9 in the Journal of the American Medical Association . “This trial showed no benefit of active treatment of the PDA in extremely preterm infants,” said lead researcher Dr. Matthew Laughon , a neonatologist at the University of North Carolina School of Medicine in Chapel Hill. “In fact, it identified a higher chance of survival for (wait-and-see) expectant management, consistent with emerging data on the effects of early (i.e., prior to one or two weeks after birth) pharmacologic PDA treatment,” he said in a news release. PDA occurs when a small blood vessel in the heart remains open after birth, researchers said in background notes. The defect places stress on the heart and the lungs, as they have to work harder to deliver blood throughout the body. Researchers compared it to drinking through a straw that has a hole in it. Every baby is born with this opening, according to the American Heart Association . It typically closes in most full-term infants soon after birth, but closure is often delayed among preemies and might not occur until after they’ve left the hospital, researchers said. Treatment of PDA remains controversial among doctors, with no clear consensus on guidelines indicating the best approach, researchers said. “There is wide variation in treatment of PDA in preterm infants,” Laughon said. “Some clinicians always treat, and some clinicians never treat. We need to know which one is better for babies.” For the study, researchers enrolled 482 extremely pre-term infants with PDAs. All the babies were born between 22 and 28 weeks of gestation. The preemies were randomly assigned to one of two groups — those who were managed with a wait-and-see approach, and those who received drugs like acetaminophen , indomethacin or ibuprofen to try to close the open blood vessel. Results showed that about 4% of infants treated with the “wait and see” died within 36 weeks of postmenstrual age, which is the sum of a baby’s length of gestation and their post-delivery age. That compared with nearly 10% among those treated with drugs. The medications used to treat PDA come with side effects that can affect a baby’s survival odds, researchers said. They can alter the immune system, reduce blood flow to the intestine, or cause injury to the mucous membranes of the GI system, leading to serious conditions like sepsis or death of intestinal tissue. These results should be used to inform treatment strategies on PDA, potentially saving more lives, researchers concluded. Sources University of North Carolina School of Medicine, news release, Dec. 10, 2025

AHAClinical Result

26 Sep 2025

·www.prnewswire.com

Sen-Jam Pharmaceutical and KVK Tech Complete Final CMC Deliverables for SJP-002C, Paving the Way for Late-Stage Clinical Development

Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam's leadership in immunoregulation and inflammaging. HUNTINGTON, N.Y., Sept. 26, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, in partnership with KVK Tech, today announced the successful completion of the final development deliverables under their Development, Manufacturing, Distribution, and Licence Agreement. KVK Tech has manufactured the required submission batches of SJP-002C and finalized the Chemistry, Manufacturing, and Controls (CMC) package, meeting FDA standards and positioning the program for Phase 2b/3 clinical trials. SJP-002C is a patented novel combination of indomethacin, a potent non-steroidal anti-inflammatory drug, and ketotifen, an H1-antihistamine and mast cell stabilizer. Together, they address inflammation while reducing the gastrointestinal risks typically associated with NSAIDs. "This milestone is about more than manufacturing readiness," said Jackie Iversen, RPh, MS, Co-Founder and Head of Clinical Development at Sen-Jam Pharmaceutical. "It reflects our broader mission to advance a new class of immunoregulators that restore balance to the immune system. By targeting inflammaging and immunosenescence, we are building a pipeline with potential far beyond acute conditions—positioning SJP-002C as both a near-term therapeutic and part of a longer-term longevity strategy." "We are proud to support Sen-Jam by completing the submission batches and CMC package for SJP-002C," said Kiran Vepuri, Executive Vice President of Business Development at KVK Tech. "Our focus has been on quality and readiness so that Sen-Jam can proceed into late-stage clinical studies without delay. As both a strategic partner and equity holder in Sen-Jam, we are deeply committed to advancing much-needed therapies together." Importance of the Milestone Regulatory Readiness: Completion of three validated submission batches and a full CMC package suitable for late-stage clinical and regulatory requirements. De-Risking the Program: Manufacturing and stability work complete, allowing clinical development to advance on schedule. Scientific & Strategic Validation: Recent commentary from Oppenheimer Research noted the role of immunoregulators in addressing inflammaging, highlighting Sen-Jam's pipeline as a differentiated opportunity in the longevity sector. Strong Intellectual Property: Sen-Jam's global patent estate, now including a manufacturing process patent for SJP-002C, provides robust protection and commercialization leverage. Next Step – Phase 2b/3 Trials: With CMC deliverables complete, SJP-002C is now positioned to begin the next phase of clinical testing. About Sen-Jam Pharmaceutical Sen-Jam Pharmaceutical is pioneering a new era of anti-inflammatory therapeutics, combining speed-to-market with accessibility and global health impact. Backed by more is raising capital at wefunder.com/senjam About KVK Tech KVK Tech is a U.S.-based, FDA-registered pharmaceutical manufacturer committed to providing high-quality, affordable medicines. With state-of-the-art facilities and deep expertise in formulation and CMC, KVK partners serves as Sen-Jam's exclusive U.S. manufacturing and distribution partner, KVK Tech is also an equity holder in Sen-Jam, underscoring its long-term commitment to the success of SJP-002C and future programs. CONTACT INFORMATION: Sen-Jam Pharmaceutical Christine Leonard 781-913-1902 [email protected] SOURCE Sen-Jam Pharmaceutical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/in

100 Deals associated with Indomethacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00141	Indomethacin	C01EB03 S01BC01 M01AB01	DB00328

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	United States	Genus Lifesciences, Inc.	24 Feb 2014
Ductus Arteriosus, Patent	United States	Fresenius Kabi USA LLC	17 Mar 2010
Inflammation	Japan	Hisamitsu Pharmaceutical Co., Inc.	06 Oct 1989
Myalgia	Japan	Teikoku Seiyaku Co. Ltd.	06 Oct 1989
Tennis Elbow	Japan	Teikoku Seiyaku Co. Ltd.	06 Oct 1989
Arthritis, Gouty	United States	Rising Pharmaceuticals, Inc.	20 Apr 1984
Periarthritis	Japan	Kowa Co., Ltd.	18 Mar 1980
Tenosynovitis	Japan	Kowa Co., Ltd.	18 Mar 1980
Tumescence	Japan	Kowa Co., Ltd.	18 Mar 1980
Pain	Japan	Kowa Co., Ltd.	18 Mar 1980
Ankylosing Spondylitis	United States	Zyla Life Sciences US LLC	10 Jun 1965
Bursitis	United States	Zyla Life Sciences US LLC	10 Jun 1965
Osteoarthritis	United States	Zyla Life Sciences US LLC	10 Jun 1965
Primary gout	United States	Zyla Life Sciences US LLC	10 Jun 1965
Rheumatoid Arthritis	United States	Zyla Life Sciences US LLC	10 Jun 1965
Shoulder Pain	United States	Zyla Life Sciences US LLC	10 Jun 1965
Tendinopathy	United States	Zyla Life Sciences US LLC	10 Jun 1965

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	China	Teikoku Seiyaku Co. Ltd.	10 Oct 2013
Low Back Pain	Phase 3	China	Beijing Century Liwei Pharmaceutical Technology Development Co., Ltd.	10 Oct 2013
Soft Tissue Injuries	Phase 3	China	Beijing Century Liwei Pharmaceutical Technology Development Co., Ltd.	10 Oct 2013
Soft Tissue Injuries	Phase 3	China	Teikoku Seiyaku Co. Ltd.	10 Oct 2013
Soft tissue pain	Phase 3	China	Teikoku Seiyaku Co. Ltd.	10 Oct 2013
Soft tissue pain	Phase 3	China	Beijing Century Liwei Pharmaceutical Technology Development Co., Ltd.	10 Oct 2013
Acute migraine	Phase 3	United States	Novartis AG	01 Oct 2013
Osteoarthritis, Knee	Phase 3	China	Beijing Century Liwei Pharmaceutical Technology Development Co., Ltd.	27 Sep 2013
Osteoarthritis, Knee	Phase 3	China	Teikoku Seiyaku Co. Ltd.	27 Sep 2013
Pain, Postoperative	Phase 3	United States	Iroko Pharmaceuticals LLC	01 Feb 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04207060 (PAIR, Pubmed \| Clin Transl Gastroenterol)	Phase 1/2	Pancreatitis, Chronic	27	Indomethacin 50 mg	nefrcfdutz(vgrgtznemt): P-Value = 0.25 View more	Negative	01 Sep 2025
				Placebo
NCT04207060 (PAIR, CTgov)	Phase 1/2	Pancreatitis, Chronic	27	Endoscopy for Pancreatic Function Testing+Indomethacin (Indomethacin)	rsteliolqv(cmjtgxpzrb) = vnoyszdaif nmgmqwnfpk (wzgwjmyymf, 489.8) View more	-	04 Sep 2024
				Placebo (Placebo)	rsteliolqv(cmjtgxpzrb) = hvxczeqwed nmgmqwnfpk (wzgwjmyymf, 865.6) View more
DDW2024	Not Applicable	Visible Lesion \| Pancreatitis	-	RECTAL INDOMETHACIN (No Prophylaxis)	txmcoymnjg(uqvxsgawev) = 1 case of acute renal failure was noted in the no prophylaxis group sqtykbanpd (kyauzuqykj ) View more	-	20 May 2024
NCT02950259 (P212, CTgov)	Phase 1	Male Breast Neoplasms \| Triple Negative Breast Cancer \| Early Stage Breast Carcinoma	16	Multivitamin+Indomethacin+Omeprazole+Cyclophosphamide (IRX-2 Regimen -Early Stage Breast Cancer)	lwllbfknxp = paurkpzifh fdntpefnzb (lhcblrvdyu, bwjvcfqcgx - dkxtfiwyrz) View more	-	30 Jan 2024
				Multivitamin+Indomethacin+Omeprazole+Cyclophosphamide (IRX-2 Regimen -Triple Negative Breast Cancer)	lwllbfknxp = azgxosvpom fdntpefnzb (lhcblrvdyu, rsuuijqufc - ctfbipuugz) View more
NCT02797067 (RIPEP, CTgov)	Phase 4	Post-ERCP Pancreatitis	1,370	indomethacin suppository (Indomethacin)	rloeevtbfi = inazecvchd mvnusyqbkz (mmrfausxzd, rmbkwkrngh - itrfktdjgy) View more	-	26 May 2022
				Glycerin Suppository (Glycerin)	rloeevtbfi = onjeylnrzl mvnusyqbkz (mmrfausxzd, xvdwtkutrc - wmwpisxipv) View more
NCT02797067 (RIPEP, Pubmed \| Lancet Gastroenterol Hepatol) Manual	Phase 4	Pancreatitis	1,370	indometacin	nyzmicxeou(ficyidrpxq) = xfkegmbqee apemkcfuvl (nzscgdpogw ) View more	Positive	01 Mar 2022
				Placebo	nyzmicxeou(ficyidrpxq) = xiqrhxchxy apemkcfuvl (nzscgdpogw ) View more
NCT02438371 (CTgov)	Phase 4	Obstetric Labor, Premature	49	Nifedipine (Nifedipine)	klkfhvopew = pccbrzpzva tckocdkikt (bjtordxnmk, pcnoehjjrc - ryymgtqqqw) View more	-	24 Nov 2021
				Indomethacin+Nifedipine (Nifedipine Plus Indomethacin)	klkfhvopew = qfbbeudprr tckocdkikt (bjtordxnmk, odcensubfw - zkkrlarzxz) View more
NCT03129945 (CTgov)	Not Applicable	Obstetric Labor, Premature	36	Nifedipine (Nifedipine)	wqeiijcxfy = ywawqwecod tdaaqvyals (wxtvutazcs, qillvoljoo - jujpwrprum) View more	-	05 Nov 2021
				Indomethacin (Indomethacin)	wqeiijcxfy = nyuwqrysvf tdaaqvyals (wxtvutazcs, ddxkwhpwib - qjoadbvmnv) View more
IRCT20080921001264N11 (Pubmed \| J Clin Gastroenterol)	Phase 4	Post-ERCP Pancreatitis	530	Intravenous Somatostatin + Rectal Indomethacin	rdhimwfxpm(wydwhqtmdt) = PEP was the most common adverse event with 50 (13.2%) episodes, including 21 (5.5%) mild, 23 (6.1%) moderate, and 6 (1.2%) severe okaeoaaafh (lqyjqnvgdo )	Negative	28 May 2021
				Placebo + Rectal Indomethacin
NCT02692391 (CTgov)	Phase 3	Pancreatitis	42	Placebo (Placebo)	bswfoghkxd(wejuzhyshy) = xixlkcatjm vxdbtffvdu (vfugfrgmss, 0.81) View more	-	22 Apr 2021
				Indomethacin (Indomethacin Suppository)	bswfoghkxd(wejuzhyshy) = mvmfcsmiwb vxdbtffvdu (vfugfrgmss, 1.24) View more